Takeda Industry Symposium
Let’s get real: Modern management of RRMM in older patients
Friday, May 12, 2023
08:30–09:30 CEST
Professor Philippe Moreau
Chair
Dr Hira Mian
Dr Paul Richardson
Agenda
| Welcome and introductions |
| Session 1: Closing the gap: Unmet needs in older patients with RRMM |
| Session 2: Treatment approaches for older patients with RRMM |
| Session 3: Interactive ‘How I treat’ case studies |
| Session 4: What’s on the horizon for the treatment of older patients with RRMM? |
| Q&A and closing remarks |
Principal objective
Our goal is to educate on the treatment of multiple myeloma, especially with respect to treatment options and, in particular, treatment in elderly fit and/or frail populations. Other patient populations include the indolent/biochemical relapsed patients and patients who have already been exposed to lenalidomide or daratumumab in prior lines of treatment.
Symposium learning objectives
Following attendance of this symposium, participants should be able to:
- Describe the need for communicating real-world clinical expertise in managing MM in older and/or frail patients who are not adequately represented in clinical trials – Philippe Moreau
- Identify factors that should be considered when selecting a treatment for older and/or frail patients with MM – Hira Mian
- State when frailty should be measured – Hira Mian
- Recall data for emerging therapies for RRMM – Paul Richardson